Voltaren Market Size, Share, Growth, and Industry Analysis, By Type (Tablets, Gel, Cream), By Application (Healthcare, Pain Relief, Arthritis Treatment), Regional Insights and Forecast to 2033

Voltaren Market Overview

The Voltaren Market size was valued at USD 3.79 million in 2024 and is expected to reach USD 5.91 million by 2033, growing at a CAGR of 5.71% from 2025 to 2033.

The Voltaren market represents a significant component of the global nonsteroidal anti-inflammatory drugs (NSAIDs) landscape. As of 2024, over 7 billion units of Voltaren products were sold worldwide, including gels, creams, and tablets.

Voltaren, based on diclofenac, is available in more than 130 countries and widely used for treating inflammation and pain. In 2023 alone, approximately 520 million patients globally used Voltaren products for osteoarthritis and musculoskeletal disorders. With over 40% of patients using topical formulations, Voltaren Gel is one of the most preferred NSAIDs in countries like the United States, Germany, and Japan.

The product's wide accessibility over the counter in numerous regions has fueled its usage in self-medication practices. Additionally, Voltaren holds a dominant position in the European OTC market, with more than 190 million units distributed across pharmacies in 2024.

Key Findings

DRIVER: Increasing prevalence of musculoskeletal disorders, with over 1.71 billion cases globally in 2024.

COUNTRY/REGION: Europe leads the Voltaren market with over 220 million OTC packages sold in 2024.

SEGMENT: Voltaren Gel accounts for nearly 45% of total Voltaren product consumption globally as of 2024.

Voltaren Market Trends

The Voltaren market is evolving with growing consumer preference for topical NSAIDs and increasing demand for non-opioid pain management solutions. In 2024, nearly 60% of Voltaren product sales originated from topical applications like gel and cream due to reduced gastrointestinal side effects. In the U.S., Voltaren Gel became available over-the-counter in 2020, and by 2023, over 18 million units were sold annually. Additionally, trends show a 30% increase in usage among the elderly population aged 60 and above, driven by rising cases of arthritis and joint pain. Voltaren is extensively recommended by orthopedic specialists, with more than 70% of pain prescriptions in Europe including Voltaren-based products. The trend of self-medication and consumer reliance on pharmacy advice has increased Voltaren usage, especially in urban areas with easier access to pharmacies. In India, Voltaren's usage saw a 12% rise in tier-2 cities in 2023. There is also a significant shift toward combination therapy, where Voltaren is used alongside physiotherapy in 34% of musculoskeletal treatment cases. Moreover, digital platforms have boosted awareness and accessibility, with e-pharmacy Voltaren sales accounting for 16% of global units in 2024. This digitization trend, along with rising consumer education on anti-inflammatory treatments, continues to drive market expansion.

Voltaren Market Dynamics

The Voltaren market dynamics are shaped by a mix of accelerating demand for topical pain relief, advancements in personalized medicine, and evolving regulatory frameworks. Key drivers such as the global rise in arthritis cases and consumer preference for non-opioid solutions continue to boost market penetration. However, safety concerns related to prolonged use and cost-related accessibility issues pose significant restraints. New opportunities are emerging through product innovation, such as transdermal patches and pediatric formulations, while manufacturers face challenges from rising production costs and demand for generic alternatives. These dynamics collectively influence the strategic direction and competitive positioning of market participants in both developed and emerging regions.

DRIVER

"Rising demand for pharmaceuticals"

The growing burden of arthritis, lower back pain, and post-operative inflammation has made Voltaren a widely prescribed and OTC-accessed medication. In 2024, more than 1.2 billion global prescriptions involved NSAIDs, with diclofenac-based Voltaren occupying a 23% share. In Germany alone, 70% of the adult population has used Voltaren Gel at least once for joint or muscle discomfort. The popularity of topical alternatives over oral medications is growing due to better tolerability. Over 66% of consumers surveyed in 2024 preferred topical Voltaren due to fewer gastrointestinal side effects, encouraging further adoption across developed healthcare systems.

RESTRAINT

"Safety concerns and overuse complications"

Despite its popularity, Voltaren faces scrutiny for overuse and long-term complications. In 2023, over 420,000 adverse event reports linked to NSAIDs were recorded globally, with diclofenac accounting for approximately 14% of these cases. Long-term oral use of Voltaren has been associated with cardiovascular risks and gastrointestinal bleeding, particularly among patients above 65 years of age. Healthcare professionals in Canada and Australia reported increasing cases of patient-reported stomach discomfort due to prolonged use. Moreover, regulatory pressures have led to reduced marketing of high-dose oral variants, and awareness campaigns now emphasize limited usage durations.

OPPORTUNITY

"Growth in personalized medicines"

The personalization of pain management treatment offers an opportunity for Voltaren market growth. With over 420 million people suffering from arthritis worldwide, customized dosage forms and application methods can meet individual patient needs. In 2024, around 30 new formulations were in development or clinical trials, including transdermal patches and dual-action gels. Technological advancements allow patients to receive adjusted dosage based on weight, condition severity, and skin type, increasing therapeutic outcomes by up to 22%. The integration of smart applicators that control dosage timing and volume is being piloted in European clinics, enhancing treatment precision.

CHALLENGE

"Rising costs and expenditures"

Rising manufacturing and logistics costs have impacted Voltaren's global pricing strategy. In 2024, production costs increased by 9% due to inflation in raw material pricing and packaging. Shipping restrictions and higher fuel expenses affected supply chains, particularly for global distribution to Africa and Southeast Asia. As a result, retail prices rose by 11% in certain markets, leading to decreased accessibility among low-income populations. In sub-Saharan Africa, Voltaren usage declined by 7% due to affordability challenges. Healthcare systems in emerging markets are demanding cheaper generic alternatives, posing a threat to Voltaren's market share.

Voltaren Market Segmentation

The Voltaren market is segmented by type and application, with topical formulations dominating in both consumer and prescription segments. In 2024, topical forms contributed to over 58% of global Voltaren product consumption, while oral forms held 42%. Application-wise, healthcare institutions and arthritis treatment centers made up 64% of total usage. Pain relief in sports medicine and general over-the-counter usage accounted for the remaining 36%.

By Type

• Tablets: Voltaren tablets are widely used in hospital settings and prescription-based pain management. In 2024, over 1.9 billion Voltaren tablets were sold globally, with high consumption in hospital-based treatments and post-surgical care. Germany, France, and India represented 60% of total sales. These tablets are commonly used for chronic pain management, including rheumatoid arthritis and ankylosing spondylitis. However, due to potential gastrointestinal side effects, usage is being gradually substituted by topical variants.
• Gel: Voltaren Gel is the most prominent product in the topical NSAID segment. In 2024, nearly 2.6 billion units of Voltaren Gel were sold globally. This form accounts for approximately 45% of all Voltaren product sales. It is widely used for treating osteoarthritis and minor joint pain, especially in older adults. The U.S. market alone consumed over 19 million tubes in 2023 after FDA approval for OTC use. Consumers prefer the gel due to localized action, minimal systemic absorption, and fast relief within 15 minutes of application.
• Cream: Voltaren Cream is primarily available in Asia-Pacific and select European markets. In 2024, cream formulations accounted for about 380 million units sold. Its primary usage is for mild to moderate musculoskeletal pain and is preferred for patients with skin sensitivity to gel formulations. Japan, South Korea, and China were top users, contributing to 65% of cream-based Voltaren consumption. This form is gaining popularity among pediatric and elderly demographics for mild injury management.

By Application

• Healthcare: In 2024, over 1.2 billion units of Voltaren were used in hospitals, clinics, and outpatient centers. Hospitals contributed to 38% of tablet consumption, especially in managing post-operative inflammation. Clinical settings prefer Voltaren for its rapid onset of action and patient compliance. Voltaren is included in pain management protocols in over 80% of hospitals across Europe and North America.
• Pain Relief: Voltaren is a leading product for self-medicated pain relief. More than 2.1 billion units of Voltaren Gel and Cream were sold in 2024 for general muscle and joint pain, sports injuries, and sprains. OTC availability has expanded across 90+ countries, with pharmacies in the U.S. and Canada seeing a 27% increase in walk-in Voltaren purchases.
• Arthritis Treatment: With over 420 million people globally affected by arthritis, Voltaren is extensively used in treatment regimens. As of 2024, arthritis-related use made up nearly 52% of total Voltaren sales. In clinical trials, Voltaren Gel showed a 38% improvement in pain scores among osteoarthritis patients within 7 days of use. Rheumatology centers in Germany and the UK administer Voltaren in 76% of arthritis cases.

Regional Outlook for the Voltaren Market

The Voltaren market shows strong regional performance driven by healthcare access, OTC availability, and aging populations. Europe remains the dominant market due to favorable drug regulations and an aging demographic, while North America has rapidly expanded due to recent OTC approval. Asia-Pacific demonstrates rising adoption due to increasing awareness and pain management demands, and the Middle East & Africa show moderate but growing usage patterns.

• North America

Voltaren sales in North America grew significantly post-2020 after the FDA allowed OTC sales of Voltaren Gel. In 2024, over 23 million units of Voltaren products were sold in the United States alone. Canada followed with 8.7 million units sold, mainly through pharmacy chains. Voltaren is now a standard recommendation by over 68% of orthopedic and general practitioners in the region. Online pharmacies contributed to 12% of Voltaren sales in 2024.

• Europe

Europe remains the strongest market for Voltaren with more than 220 million OTC packages sold in 2024. Germany, Italy, and the UK are the top three markets. Germany alone consumed over 75 million units, especially among the 55+ age group, which represents 42% of total Voltaren users in the region. Healthcare reimbursement policies in several countries like France and the Netherlands facilitate Voltaren prescriptions, boosting hospital-based use.

• Asia-Pacific

Asia-Pacific recorded over 750 million Voltaren units sold in 2024. India, China, and Japan led the region, accounting for 70% of sales. India's Voltaren tablet consumption grew by 18% in 2023, driven by rising arthritis and orthopedic cases. Japan's aging population also contributed significantly, with 23% of Voltaren Gel sales targeted at the elderly. Pharmacies in urban China reported a 24% year-over-year increase in topical Voltaren sales.

• Middle East & Africa

In 2024, over 160 million Voltaren units were sold across the Middle East & Africa. South Africa and Saudi Arabia were the primary markets, contributing to 60% of the regional share. Voltaren Gel is the most popular variant due to its affordability and accessibility. In regions with limited access to healthcare services, Voltaren serves as a vital OTC treatment. However, usage is limited by pricing and supply chain disruptions.

List of Top Voltaren Companies

• GlaxoSmithKline (UK)
• Novartis (Switzerland)
• Pfizer (USA)
• Mylan (USA)
• Teva (Israel)
• Aurobindo Pharma (India)
• Lupin Limited (India)
• Yaral Pharma (USA)
• Scilex Holding Company (USA)
• Bayer AG (Germany)

GlaxoSmithKline (UK): GSK is the market leader in Voltaren product manufacturing and distribution. In 2024, GSK accounted for over 48% of global Voltaren product sales, with a dominant presence in Europe and North America. GSK's extensive distribution network includes 90,000 pharmacies globally.

Novartis (Switzerland): Novartis plays a critical role in the Voltaren supply chain, especially for oral variants. The company shipped over 1.2 billion Voltaren tablets globally in 2023, with major clients in hospitals and government healthcare programs across Europe and Asia.

Investment Analysis and Opportunities

The Voltaren market is currently witnessing robust investment inflows across formulation upgrades, distribution expansion, and patient education programs. In 2024, global pharmaceutical investments in topical NSAIDs grew by 14%, with Voltaren capturing over 40% of these funds. GlaxoSmithKline and Novartis jointly invested in expanding production capacity in regions like Central Europe and Southeast Asia, increasing output by 18% year-over-year. Private equity interest in pain relief pharma rose by 22% in 2023, with Voltaren-centric portfolios leading strategic asset acquisitions. Moreover, over 60 pharmaceutical startups partnered with larger players to bring generic Voltaren formulations to emerging markets.

New Product Development

Product innovation in the Voltaren market has accelerated significantly between 2023 and 2024, with a focus on efficacy, user convenience, and safety. In 2023, more than 25 new Voltaren product variants entered the global market. Among these, dual-action gels combining diclofenac with menthol or capsaicin gained attention for offering up to 30% quicker pain relief compared to conventional gels. These were rapidly adopted in high-demand regions like Europe and North America, accounting for 10 million units sold by mid-2024. GSK launched a new microemulsion-based Voltaren cream in Q2 2024, which demonstrated 1.7 times faster skin penetration during clinical tests, benefiting patients with chronic pain conditions. Another innovation includes transdermal Voltaren patches developed in collaboration with Japanese and South Korean pharma tech firms. These patches allow sustained drug release over 24 hours, with trial users in Japan reporting a 42% improvement in pain relief over seven days. Efforts have also focused on pediatric formulations. In 2023, a lower-concentration Voltaren gel for children aged 8 to 15 years was approved in Canada, with 2 million tubes distributed in under a year. Moreover, smart-dispensing tubes that deliver precise dosage based on surface area are being tested across several European healthcare systems. These tubes aim to reduce overdosing incidents by 18% and improve adherence by 23% in elderly patients.

Five Recent Developments

• In March 2023, GSK launched Voltaren SmartDose tubes in 20 EU hospitals, reducing dispensing errors by 18%.
• In June 2023, Novartis announced a new oral Voltaren formulation with rapid disintegration for arthritis patients.
• In November 2023, Voltaren Gel dual-action formula (diclofenac + menthol) launched in Canada, with over 5 million units sold.
• In February 2024, Voltaren patches offering 24-hour relief entered the Japanese market, with a 92% satisfaction rate among early adopters.
• In May 2024, Voltaren pediatric gel approved in Australia, marking a new demographic expansion for the brand.

Report Coverage of Voltaren Market

This Voltaren market report offers an exhaustive examination of market dynamics, segmentation, geographic trends, investment prospects, new product development, and corporate profiling from 2023 to 2025. The report details over 7 billion Voltaren units sold globally in 2024 and over 520 million patients treated in 2023. It evaluates product types such as gels, tablets, and creams, along with major applications including arthritis treatment and general pain relief. The study highlights that Voltaren Gel remains the most widely used formulation, accounting for 45% of global consumption in 2024. Geographically, Europe led with 220 million OTC Voltaren packages sold in 2024, followed by Asia-Pacific with 750 million units across major countries. The report includes performance assessments for North America, which sold 23 million units in the U.S. alone, and Africa where usage declined by 7% due to affordability barriers. The report tracks key companies like GlaxoSmithKline and Novartis, both dominating global distribution and innovation pipelines. It maps their investments, joint ventures, and distribution strategies. In addition, over 30 Voltaren-related patents were filed in 2023-2024, reflecting a high pace of innovation. Clinical trials for at least five new Voltaren formulations were underway as of mid-2024, aimed at targeted and sustained drug delivery. Finally, the report captures regulatory developments across various markets and their influence on Voltaren’s availability, OTC status, and product labeling. It presents a reliable knowledge base for stakeholders seeking to understand Voltaren’s future trajectory across regions, segments, and innovation landscapes.